Ethical imperatives of timely access to orphan drugs: Is possible to reconcile economic incentives and patients' health needs?

Orphanet Journal of Rare Diseases

Volumn 12, Issue 1, 2017, Pages

  Rodriguez Monguio, R ^a   Spargo, T ^a   Seoane Vazquez, E ^b,c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Economic incentives; Ethical aspects; FDA; Orphan diseases; Orphan drugs; Rare diseases; Research and development

Indexed keywords

ANTINEOPLASTIC AGENT; ORPHAN DRUG;

ARTICLE; BUDGET; CONSENSUS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; MALIGNANT NEOPLASM; MEDICAL ETHICS; RARE DISEASE; REIMBURSEMENT; SOCIAL ASPECT; UNITED STATES; DRUG MANUFACTURE; ECONOMICS; ETHICS;

DRUG APPROVAL; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85008323951     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0551-7     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention. Chronic Diseases: The Leading Causes of Death and Disability in the United States. 2016. http://www.cdc.gov/chronicdisease/overview/index.htm. Accessed 14 Aug 2016.
2. National Institutes of Health. Genetic and Rare Disease Information Center. 2008. http://rarediseases.info.nih.gov. Accessed 18 Mar 2016.
3. United States Congress: Rare diseases Act of 2002. Public Law 107-280.
4. Wastfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260(1):1-10.
5. Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet. 2016;5(1):33-42.
6. Putzeist M, Mantel-Teeuwisse AK, Wied CC, Hoes AW, Leufkens HG, de Vrueh RL. Drug development for exceptionally rare metabolic diseases: challenging but not impossible. Orphanet J Rare Dis. 2013;8:179.
7. Miles KA, Packer C, Stevens A. Quantifying emerging drugs for very rare conditions. QGM. 2007;100(5):291-5.
8. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829-36.
9. National Institute for Clinical Excellence. NICE Citizens Council Report Ultra Orphan Drugs. 2004.
10. Food and Drug Administration: Orphan drug regulations. 1992. Final rule. 57 Fed Register 62076 21 CFR 316.
11. 21 United States Code 360bb- Designation of drugs for rare diseases or conditions. 1984.
12. European Parliament: the Orphan Regulation. 1999. 141/2000.
13. Asbury CH. The Orphan Drug Act. The first 7 years. JAMA. 1991;265(7):893-7.
14. Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821-5.
15. Food and Drug Administration. Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed 13 Aug 2016.
16. Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol. 2010;686:223-50.
17. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008;3:33.
18. Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13-14):660-4.
19. Rzakhanov Z. Regulatory Policy, Value of Knowledge Assets and Innovation Strategy: The Case of the Orphan Drug Act. Research Policy. 2008;37(4):673-89.
20. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95(2-3):216-28.
21. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42. doi: 10.1186/1750-1172-6-42.
22. Rai AK. Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Soc Philos Policy. 2002;19(2):246-70.
23. Gutierrez L, Patris J, Hutchings A, Cowell W. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10(1):53.
24. Yin W. R&D policy, agency costs and innovation in personalized medicine. J Health Econ. 2009;28(5):950-62.
25. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2014.
26. Paulden M, Stafinski T, Menon D, McCabe C. Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework. Pharmacoeconomics. 2015;33(3):255-69.
27. Tencer T, Roberson C, Duncan N, Johnson K, Shapiro A. A haemophilia treatment centre-administered disease management programme in patients with bleeding disorders. Haemophilia. 2007;13(5):480-8.
28. Tur-Kaspa I, Aljadeff G, Rechitsky S, Grotjan HE, Verlinsky Y. PGD for all cystic fibrosis carrier couples: novel strategy for preventive medicine and cost analysis. Reprod Biomed Online. 2010;21(2):186-95.
29. Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, Lochmuller H, Bushby K. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529-36.
30. Kanters TA, van der Ploeg AT, Brouwer WB, Hakkaart L. The impact of informal care for patients with Pompe disease: an application of the CarerQol instrument. Mol Genet Metab. 2013;110(3):281-6.
31. Juth N. For the Sake of Justice: Should We Prioritize Rare Diseases? Health Care Anal. 2014.
32. Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493-511.
33. Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15(4):335-40.
34. McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol. 2010;686:211-22.
35. Ehni HJ. Expensive cancer drugs and just health care. Best Pract Res Clin Gastroenterol. 2014;28(2):327-37.
36. Achelrod D, Blankart CR, Linder R, von Kodolitsch Y, Stargardt T. The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. Orphanet J Rare Dis. 2014;9:90.
37. Richesson R, Vehik K. Patient registries: utility, validity and inference. Adv Exp Med Biol. 2010;686:87-104.
38. European Court of Human Rights: The European Convention. 1948. http://www.echr.coe.int/pages/home.aspx?p=basictexts. Accessed 21 Mar 2016.
39. World Health Organization. Constitution of the World Health Organization. 1946.
40. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31(3):164-8.
41. Nitecki v. Poland. European Convention on Human Rights (ECHR). 2002. Application 65653/01.
42. Nations U. The Universal Declaration of Human Rights. 1950. http://www.un.org/en/universal-declaration-human-rights/. Accessed 21 March 2016.
43. UN Department for Economic and Social Affairs (DESA): Convention on the Rights of Persons with Disabilities. 2016. https://www.un.org/development/desa/disabilities/convention-on-the-rights-of-persons-with-disabilities.html. Accessed 21 Mar 2016.
44. American's with Disabilities Act (ADA). 1990; 42 U.S.C. § 12101.
45. Social Security Administration: Social Security Act. 1935; SEC. 1105.
46. Patient Protection and Affordable Care Act (ACA). 2010; 42 U.S.C. § 18001.
47. Hyry HI, Roos JC, Manuel J, Cox TM. The legal imperative for treating rare disorders. Orphanet J Rare Dis. 2013;8:135.
48. R(on the application of Rogers) v. Swindon NHS Primary Care Trust & another 2006 EWCA Civ:392.
49. R(on the application of Otley) v. Barking and Dagenham NHS Primary Care Trust 2007 EWHC 1927.
50. Stockklausner C, Lampert A, Hoffmann GF, Ries M. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act is Delivering-A Cross Sectional Analysis. Oncologist. 2016;21(4):487-93.
51. Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012;7(2), e31894.
52. Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff (Millwood). 2015;34(2):302-10.